StellarQ

StellarQ has been last 12 years co-operating with Finnish wellbeing service counties developing disease and treatment monitoring to long-term illnesses. We provide meaningful data to the care providers, healthcare professionals, patients, pharmaceutical companies, and research community. With this meaningful data we enable value based healthcare. At the moment we provide disease monitoring to MS disease, Movement disorders (Parkinson’s disease, Parkinson plus syndomes), Epilepsy, SMA, DMD, Huntington’s disease, Sleep apnea and respiratory failure, and to non-invasive neuromodulation therapy (and more to come). MS registry covers over 85 % of all MS patients in Finland. StellarQ has also invested in combining the information collected from the patient (PROM) as part of clinical decision-making. Patients use validated measures to produce an assessment of the severity of the illness and their quality of life. PROM is visualized as part of the healthcare professional's view.

Besides being experts on technology we are well known about substance knowledge considering neurology and other areas. This knowledge is a base for both developing technological solutions, and knowing how to gather and use the data. StellarQ provides a wide range of RWE professional services from permit process and data analysis to submission-ready study reports or manuscript.